https://www.biospace.com/kuria-therapeutics-completes-fda-pre-ind-consultation-for-topical-nrf2-activator-for-corneal-endothelial-disease
Kuria Therapeutics Completes FDA Pre-IND Consultation for Topical Nrf2 Activator for Corneal...
Mar 17, 2023 - Kuria Therapeutics is pleased to announce it has completed a pre-Investigational New Drug ("IND") interaction with the U.S. Food and Drug Administration (FDA)...
ind consultation